biostudies-literatureUnknown4(11)Morikawa T<h4>Background</h4>The MitraClip (Abbott), a percutaneous edge-to-edge mitral valve (MV) repair device, is the only approved device in Japan for mitral transcatheter edge-to-edge repair (M-TEER) therapy to treat primary and secondary mitral regurgitation (MR). Outcomes of the fourth-generation M-TEER system, featuring independent grasping, improved clip deployment, and 4 clip sizes with wider and longer clip arms, have not been reported in Japan.<h4>Objectives</h4>This study evaluates the 1-year safety and effectiveness of the fourth-generation M-TEER system in Japan to treat MR in a contemporary, real-world setting.<h4>Methods</h4>EXPAND G4 is a prospective, single-arm, international, postmarket study. One-year outcomes from subjects treated in Japan include MR severity (assessed by an ecJACC. Asia810-821https://www.ebi.ac.uk/biostudies/studies/S-EPMC11604470biostudies-literature1-Year Outcomes of Fourth-Generation Mitral Transcatheter Edge-to-Edge Repair in Japan From the EXPAND G4 Study.PMC11604470Morikawa TYamamoto MYagasaki Hvon Bardeleben RSAsami MAsch FMUeno HDong MRodriguez EEnta YPeterman KSakamoto Tfalse1-Year Outcomes of Fourth-Generation Mitral Transcatheter Edge-to-Edge Repair in Japan From the EXPAND G4 Study.<h4>Background</h4>The MitraClip (Abbott), a percutaneous edge-to-edge mitral valve (MV) repair device, is the only approved device in Japan for mitral transcatheter edge-to-edge repair (M-TEER) therapy to treat primary and secondary mitral regurgitation (MR). Outcomes of the fourth-generation M-TEER system, featuring independent grasping, improved clip deployment, and 4 clip sizes with wider and longer clip arms, have not been reported in Japan.<h4>Objectives</h4>This study evaluates the 1-year safety and effectiveness of the fourth-generation M-TEER system in Japan to treat MR in a contemporary, real-world setting.<h4>Methods</h4>EXPAND G4 is a prospective, single-arm, international, postmarket study. One-year outcomes from subjects treated in Japan include MR severity (assessed by an ec2024-01-01T00:00:00Z2024 Nov2026-06-03T03:24:12.316Z2025-04-04T01:23:47.624ZS-EPMC116044703961940010.1016/j.jacasi.2024.08.003